N-(5-{2-[2'-fluoro-4'-(3-methoxyphenylthio)biphenyl-4-yl]ethyl}-2,2-dimethyl-1,3-dioxan-5-yl)acetamide | 956037-61-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-{2-[2'-fluoro-4'-(3-methoxyphenylthio)biphenyl-4-yl]ethyl}-2,2-dimethyl-1,3-dioxan-5-yl)acetamide
• 英文别名: N-[5-[2-[4-[2-fluoro-4-(3-methoxyphenyl)sulfanylphenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide
• CAS: 956037-61-9
• 化学式: C₂₉H₃₂FNO₄S
• 分子量: 509.642
• InChiKey: FVWPJNGQUJHROJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(5-{2-[2'-fluoro-4'-(3-methoxyphenylthio)biphenyl-4-yl]ethyl}-2,2-dimethyl-1,3-dioxan-5-yl)acetamide 在 盐酸 、 水 作用下， 以 甲醇 为溶剂， 生成 2-amino-2-[2-[2'-fluoro-4'-(3-methoxyphenylthio)biphenyl-4-yl]ethyl]propane-1,3-diol hydrochloride
  参考文献：
  名称：

  Removal of Sphingosine 1-Phosphate Receptor-3 (S1P₃) Agonism is Essential, But Inadequate to Obtain Immunomodulating 2-Aminopropane-1,3-diol S1P₁ Agonists with Reduced Effect on Heart Rate

  摘要：

  A series of 2-substituted 2-aminopropane-1,3-diols having a biphenyl moiety and their phosphate esters were synthesized to obtain sphingosine 1-phosphate receptor-1 (S1P(1)) receptor agonists with potent immunomodulatory activity accompanied by little or no effect on heart rate. Many of the synthesized compounds sufficiently decreased the number of peripheral blood lymphocytes. Some of the phosphates had potent agonism at S1P(1) but no agonism at S1P(3), which had been reported to be a receptor responsible for heart rate reduction. Although high S1P(1)/S1P(3) selectivity was considered to be favorable to reduce the effect on heart rate, almost all the phosphates showed a remarkable heart rate lowering effect in vivo. The results suggest that other factors in addition to S1P(3) agonism should be responsible for the heart rate reduction caused by S1P(1) agonists. Only 2-amino-2-[2-[2'-fluoro-4'-(4-methylphenylthio)biphenyl-4-yl]ethyl]propane-1,3-diol (6d) was identified as a desired S1P(1) receptor agonist having both the immunomodulatory activity and an attenuated effect on heart rate by a unique screening flow using in vivo evaluating systems primarily.

  DOI：

  10.1021/jm901776q
• 作为产物：
  描述：

  N-[5-[2-(4'-bromo-2'-fluorobiphenyl-4-yl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl]acetamide 、 3-甲氧基苯硫酚 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-(5-{2-[2'-fluoro-4'-(3-methoxyphenylthio)biphenyl-4-yl]ethyl}-2,2-dimethyl-1,3-dioxan-5-yl)acetamide
  参考文献：
  名称：

  Removal of Sphingosine 1-Phosphate Receptor-3 (S1P₃) Agonism is Essential, But Inadequate to Obtain Immunomodulating 2-Aminopropane-1,3-diol S1P₁ Agonists with Reduced Effect on Heart Rate

  摘要：

  A series of 2-substituted 2-aminopropane-1,3-diols having a biphenyl moiety and their phosphate esters were synthesized to obtain sphingosine 1-phosphate receptor-1 (S1P(1)) receptor agonists with potent immunomodulatory activity accompanied by little or no effect on heart rate. Many of the synthesized compounds sufficiently decreased the number of peripheral blood lymphocytes. Some of the phosphates had potent agonism at S1P(1) but no agonism at S1P(3), which had been reported to be a receptor responsible for heart rate reduction. Although high S1P(1)/S1P(3) selectivity was considered to be favorable to reduce the effect on heart rate, almost all the phosphates showed a remarkable heart rate lowering effect in vivo. The results suggest that other factors in addition to S1P(3) agonism should be responsible for the heart rate reduction caused by S1P(1) agonists. Only 2-amino-2-[2-[2'-fluoro-4'-(4-methylphenylthio)biphenyl-4-yl]ethyl]propane-1,3-diol (6d) was identified as a desired S1P(1) receptor agonist having both the immunomodulatory activity and an attenuated effect on heart rate by a unique screening flow using in vivo evaluating systems primarily.

  DOI：

  10.1021/jm901776q

文献信息

• 2-Aminobutanol Compound and Use Thereof for Medical Purposes
  申请人：Kiuchi Masatoshi

  公开号：US20090082311A1

  公开（公告）日：2009-03-26

  The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect. The present invention provides a 2-aminobutanol compound represented by the following formula (I) wherein R 1 is a hydrogen atom or P(═O) (OH) 2 , R 2 is an alkyl having 1 to 4 carbon atoms optionally substituted by hydroxyl group(s) or optionally substituted by halogen atom(s), R 3 is a hydrogen atom; a halogen atom; cyano; an alkyl having 1 to 4 carbon atoms optionally substituted by halogen atom(s); or an acyl having 2 to 5 carbon atoms optionally substituted by halogen atom(s), X is an oxygen atom, a sulfur atom, carbonyl or NR 4 wherein R 4 is a hydrogen atom or an alkyl having 1 to 4 carbon atoms, Ar 1 is an optionally substituted arylene or an optionally substituted heteroarylene, and Ar 2 is an optionally substituted aryl or an optionally substituted heteroaryl, provided that when X is an oxygen atom, Ar 1 is phenylene and Ar 2 is phenyl, then the phenyl for Ar 2 should be substituted, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the above-mentioned 2-aminobutanol compound.

  本发明提供了一种新型化合物，具有较少的副作用，如心动过缓等，并具有优越的外周血淋巴细胞降低作用。本发明提供了一种由以下式（I）表示的2-氨基丁醇化合物，其中R1是氢原子或P（═O）（OH）2，R2是1至4个碳原子的烷基，可选地被羟基或卤原子取代，R3是氢原子，卤原子，氰基，1至4个碳原子的烷基，可选地被卤原子取代，或2至5个碳原子的酰基，可选地被卤原子取代，X是氧原子，硫原子，羰基或NR4，其中R4是氢原子或1至4个碳原子的烷基，Ar1是可选取代的芳烃基或可选取代的杂芳烃基，Ar2是可选取代的芳基或可选取代的杂芳基，但当X为氧原子时，Ar1为苯基，Ar2为苯基，则Ar2的苯基应被取代，或其药学上可接受的酸加盐或其水合物或溶剂化物，以及上述2-氨基丁醇化合物的制备方法。
• 2-aminobutanol compound and use thereof for medical purposes
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08114902B2

  公开（公告）日：2012-02-14

  Disclosed is a 2-aminobutanol compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the 2-aminobutanol compound of formula (I). The 2-aminobutanol compounds of formula (I) have few side effects including bradycardia and have superior peripheral blood lymphocyte-decreasing effects.

  本发明公开了一种由以下式（I）表示的2-氨基丁醇化合物，或其药学上可接受的酸加盐或水合物或溶剂化物，以及式（I）的2-氨基丁醇化合物的制备方法。式（I）的2-氨基丁醇化合物具有少量副作用，包括心动过缓，并具有优越的外周血淋巴细胞减少作用。
• 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2017257B1

  公开（公告）日：2014-08-06
• US8114902B2
  申请人：——

  公开号：US8114902B2

  公开（公告）日：2012-02-14
• Removal of Sphingosine 1-Phosphate Receptor-3 (S1P₃) Agonism is Essential, But Inadequate to Obtain Immunomodulating 2-Aminopropane-1,3-diol S1P₁ Agonists with Reduced Effect on Heart Rate
  作者：Maiko Hamada、Mitsuharu Nakamura、Masatoshi Kiuchi、Kaoru Marukawa、Ayumi Tomatsu、Kyoko Shimano、Noriko Sato、Kunio Sugahara、Mahoko Asayama、Kan Takagi、Kunitomo Adachi

  DOI：10.1021/jm901776q

  日期：2010.4.22

  A series of 2-substituted 2-aminopropane-1,3-diols having a biphenyl moiety and their phosphate esters were synthesized to obtain sphingosine 1-phosphate receptor-1 (S1P(1)) receptor agonists with potent immunomodulatory activity accompanied by little or no effect on heart rate. Many of the synthesized compounds sufficiently decreased the number of peripheral blood lymphocytes. Some of the phosphates had potent agonism at S1P(1) but no agonism at S1P(3), which had been reported to be a receptor responsible for heart rate reduction. Although high S1P(1)/S1P(3) selectivity was considered to be favorable to reduce the effect on heart rate, almost all the phosphates showed a remarkable heart rate lowering effect in vivo. The results suggest that other factors in addition to S1P(3) agonism should be responsible for the heart rate reduction caused by S1P(1) agonists. Only 2-amino-2-[2-[2'-fluoro-4'-(4-methylphenylthio)biphenyl-4-yl]ethyl]propane-1,3-diol (6d) was identified as a desired S1P(1) receptor agonist having both the immunomodulatory activity and an attenuated effect on heart rate by a unique screening flow using in vivo evaluating systems primarily.